Last mentioned: Mar 24, 2026
Market Outperformance
Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
Market Outperformance
Financial media highlights Grail as the week's top performer in the diagnostics sector.
Market Outperformance
Grail shares surge as market sentiment shifts from bearish to bullish, leading the biotech sector gains.
Volume Surge
Stock sees highest trading volume in six months as institutional buyers return.
TD Cowen Upgrade
TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
TD Cowen Upgrade
Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
TD Cowen Upgrade
Analysts upgrade GRAL, calling the recent selloff a 'buying opportunity' and stabilizing the stock price.
Market Low
GRAL stock hits a 52-week low amid heavy selling pressure.
CEO Transition & Setback
CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.
CEO Transition
Bob Ragusa steps down as CEO following reports of a trial setback.
Leadership & Trial Volatility
CEO Bob Ragusa announces retirement; reports surface regarding a setback in the NHS-Galleri clinical trial.
Analyst Target Cuts
TD Cowen and Canaccord Genuity slash price targets citing competitive risks and valuation.
Market Volatility
VEEV stock surges 11% on long-term outlook before retreating on disclosure concerns.
Q4 Earnings Report
Veeva reports advancing income and sets a $6B revenue target for 2030.
Competitive Disclosure
Management reveals competitive losses in the CRM segment during the earnings call.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
United Airlines CEO Scott Kirby has signaled that ticket prices could rise by as much as 20% if jet fuel costs remain at current elevated levels. The warning highlights the growing pressure on airline margins as energy volatility threatens to disrupt travel demand and sector profitability.
After a volatile start to March marked by a CEO transition and clinical trial setbacks, Grail (GRAL) shares staged a massive recovery this week. The rebound was fueled by a high-profile analyst upgrade and a market correction following what many saw as an overreaction to recent headwinds.
Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.
Ulta Beauty is expanding its digital footprint by launching on TikTok Shop following an 11.8% increase in net sales. The move positions the beauty giant alongside early adopters like Revolve and Pacsun as it seeks to dominate the burgeoning social commerce market.
TD Cowen and Canaccord Genuity Group have significantly lowered their price targets for Veeva Systems (VEEV) following a complex quarterly update. While the company maintains a bullish long-term revenue outlook, analysts are increasingly focused on execution risks surrounding its proprietary CRM migration and recent competitive pressures.
Veeva Systems (VEEV) is navigating a complex post-earnings landscape as major analysts, including TD Cowen and Canaccord Genuity, significantly lower their price targets. Despite a bullish long-term revenue outlook, recent management disclosures regarding competitive losses have triggered a wave of valuation adjustments across Wall Street.
Veeva Systems is facing a wave of price target reductions from major analysts, including TD Cowen and Canaccord Genuity, reflecting caution over its platform transition. While management maintains a $6 billion revenue target for 2030, recent disclosures of competitive losses have tempered market enthusiasm.
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
TD Cowen has downgraded digital intelligence leader Cellebrite (CLBT), citing a broader contraction in the forensics market. Despite the company's robust annual recurring revenue growth, analysts warn that tightening government budgets and market saturation could limit near-term upside.